NeuroPace Inc (NAS:NPCE)
$ 9.225 2.085 (29.2%) Market Cap: 269.34 Mil Enterprise Value: 226.00 Mil PE Ratio: 0 PB Ratio: 27.13 GF Score: 52/100

Neuropace Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 07:30PM GMT
Release Date Price: $18.1 (-5.48%)
Andrew Christopher Ranieri
Morgan Stanley, Research Division - Equity Analyst

Thank you everyone for joining us this afternoon for another session at the Morgan Stanley Healthcare Conference. I'm Drew Ranieri, one of the medical device analysts here. From NeuroPace, it's my pleasure to have CEO, Mike Favet and CFO, Rebecca Kuhn with us here today for a fireside chat. Before we jump into that, just a brief disclaimer. For important disclosures, please see morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, Mike and Rebecca, thank you so much for taking the time here today. Looking forward to the discussion.

Michael L. Favet
NeuroPace, Inc. - President, CEO & Director

Thanks Drew, appreciate the opportunity.

Questions & Answers

Andrew Christopher Ranieri
Morgan Stanley, Research Division - Equity Analyst

And maybe first, just given that you are a newer company from a public perspective, just give us a brief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot